Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez Abad, Maria
Calvo, Isabel
Martinez, Noelia
Herrero, Mercedes
Quijano, Yolanda
Duran, Hipolito
Garcia Aranda, Mariola
Suarez, Ana
Lopez-Rios, Fernando
Perez, Diego
Perea, Sofia
Hidalgo, Manuel
Garca-Estevez, Laura
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa Sol, Marbella, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute
    Yardley, Denise A.
    Zubkus, John D.
    Eakle, Janice F.
    Bechhold, Rebecca G.
    Finney, Lindsey
    Daniel, Davey
    Daniel, Brooke
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2015, 15 (04) : 251 - 258
  • [32] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [33] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing Mirn
    Adelson, Kerin B.
    Crew, Katherine D.
    Chuang, Ellen
    Makower, Della
    Hershman, Dawn L.
    Califano, Andrea
    Silva, Jose
    Maurer, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Patel, Tejal A.
    Ensor, Joe E.
    Creamer, Sarah L.
    Boone, Toniva
    Rodriguez, Angel A.
    Niravath, Poly A.
    Darcourt, Jorge G.
    Meisel, Jane L.
    Li, Xiaoxian
    Zhao, Jing
    Kuhn, John G.
    Rosato, Roberto R.
    Qian, Wei
    Belcheva, Anna
    Schwartz, Mary R.
    Kaklamani, Virginia G.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [35] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
    Tejal A. Patel
    Joe E. Ensor
    Sarah L. Creamer
    Toniva Boone
    Angel A. Rodriguez
    Poly A. Niravath
    Jorge G. Darcourt
    Jane L. Meisel
    Xiaoxian Li
    Jing Zhao
    John G. Kuhn
    Roberto R. Rosato
    Wei Qian
    Anna Belcheva
    Mary R. Schwartz
    Virginia G. Kaklamani
    Jenny C. Chang
    Breast Cancer Research, 21
  • [36] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
    Levaggi, A.
    Poggio, F.
    Lambertini, M.
    D'Alonzo, A.
    Giraudi, S.
    Bighin, C.
    Blondeaux, E.
    Pastorino, S.
    Abate, A.
    Iacono, G.
    Vaglica, M.
    Conte, B.
    Pronzato, P.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
    Semiglazov, V.
    Eiermann, W.
    Manikhas, A.
    Bozok, A.
    Lluch, A.
    Tjulandine, S.
    Feyereislova, A.
    Valagussae, P.
    Baselga, J.
    Gianni, L.
    EJC SUPPLEMENTS, 2008, 6 (07): : 169 - 170
  • [39] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    Lopresti, M. L.
    Bian, J. J.
    Sakr, B. J.
    Strenger, R. S.
    Legare, R. D.
    Fenton, M.
    Witherby, S. M.
    Dizon, D. S.
    Pandya, S. V.
    Stuckey, A. R.
    Edmondson, D. A.
    Gass, J. S.
    Emmick, C. M.
    Graves, T. A.
    Cutitar, M.
    Olszewski, A. J.
    Sikov, W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 93 - 101
  • [40] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    M. L. Lopresti
    J. J. Bian
    B. J. Sakr
    R. S. Strenger
    R. D. Legare
    M. Fenton
    S. M. Witherby
    D. S. Dizon
    S. V. Pandya
    A. R. Stuckey
    D. A. Edmondson
    J. S. Gass
    C. M. Emmick
    T. A. Graves
    M. Cutitar
    A. J. Olszewski
    W. M. Sikov
    Breast Cancer Research and Treatment, 2021, 189 : 93 - 101
12345